BioCentury
ARTICLE | Clinical News

Fostamatinib disodium: Phase III started

August 11, 2014 7:00 AM UTC

Rigel began a pair of identical double-blind, placebo-controlled Phase III trials to evaluate twice-daily 100 mg oral fostamatinib in a total of 150 patients with persistent or chronic ITP with platel...